or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 (Former name, former address and former fiscal year, if changed since last report) For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exact name of registrant as spe ...

Exhibit 99.1 ICU Medical Announces First Quarter 2024 Results SAN CLEMENTE, Calif., May 7, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024. Revenues by product line for the three months ended March 31, 2024 and 2023 were as follows (in millions): First Quarter 2024 Results First quarter 2024 revenue was $566.7 million, compared to $568.6 ...

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. ...

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. ...

ICU Medical, Inc. (NASDAQ:ICUI) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants John Mills - Managing Partner at ICR Vivek Jain - CEO and Chairman Brian Bonnell - CFO Conference Call Participants Jayson Bedford - Raymond James Larry Solow - CJS Securities Kristen Stewart - CL King Brett Fishbin - KeyBanc Operator Good day, and welcome to the ICU Medical, Inc. Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 33-0022692 (State or other jurisdiction of incorporation or ...

Exhibit 99.1 ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., February 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit f ...

ICU Medical, Inc. (NASDAQ:ICUI) Q3 2023 Results Conference Call November 6, 2023 4:30 PM ET Company Participants John Mills - Managing Partner at ICR Vivek Jain - Chief Executive Officer and Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Larry Solow - CJS Securities Jayson Bedford - Raymond James Operator Good afternoon. And welcome to the ICU Medical Inc. Third Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note, this event is being recorded. I would l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorpo ...

Financial Data and Key Metrics - Q2 2023 GAAP revenue was $549 million, down 2% on a reported basis and 1% on a constant currency basis compared to $561 million last year [6] - Adjusted SG&A expense was $110 million, and adjusted R&D was $22 million in Q2, with adjusted operating expenses down 2% year-over-year [7] - Adjusted EBITDA for Q2 increased 16% to $98 million compared to $85 million last year [72] - Adjusted diluted EPS for Q2 was $1.88, up 37% from $1.37 last year [72] - Full-year adjusted EBITDA guidance narrowed to $375 million to $405 million, and adjusted EPS guidance narrowed to $6 to $6.85 per share [73][74] Business Unit Performance - Consumables business unit revenue was $237 million, down 1% on a constant currency basis and 2% reported, driven by growth in ICU IV therapy but offset by declines in Vascular Access [2] - Infusion Systems revenue was $153 million, up 5% constant currency and 3% reported, with growth in ambulatory and syringe product lines [55] - Vital Care revenue was $145 million, down 7% constant currency, primarily due to declines in IV Solutions [56] - Legacy ICU portfolio grew, but IV Solutions faced challenges, including a weak April and issues with Pfizer-supplied products [52] Market and Competitive Environment - The company is focused on regaining lost revenues in acquired categories, with Vascular Access being the primary challenge, estimated to be $20 million to $25 million short for the year [52][80] - The company is working on manufacturing consolidations and real estate adjustments to improve gross margins medium and long term [82] - The competitive environment in infusion systems remains stable, with customers expecting all market participants to be available, which may have delayed purchasing decisions [100] Strategic Direction and Industry Competition - The company is focused on integrating its manufacturing and distribution networks to capture synergies and improve operational efficiency [58] - The company aims to be a reliable supplier with a multiyear innovation portfolio and optimized manufacturing network [43] - The company is addressing quality remediation and regulatory compliance, with significant investments in resolving FDA warning letters and improving quality systems [61][66] Management Commentary on Operating Environment and Outlook - Management highlighted operational stability and growth in most businesses but acknowledged delays in Vascular Access revenue recovery [51][80] - The company expects sequential improvement in all product lines for the remainder of the year, though Vascular Access delays will impact overall growth rates [54] - Management emphasized the importance of inventory management and production efficiency to improve free cash flow and gross margins [76][88] Other Key Information - The company transitioned away from Smiths Group's IT systems and is now focused on ERP integration to optimize logistics and service networks [58] - Inventory levels peaked in Q2, with a $27 million increase, roughly half the recent historical average, and the company expects to slow inventory builds further in the second half of the year [88] - The company spent $12 million on restructuring and integration in Q2, primarily related to the acquisition [72] Q&A Session Summary Question: Impact of Vascular Access revenue shortfall - The company acknowledged a $20 million to $25 million shortfall in Vascular Access revenue for the year, primarily due to delays in new business and operational challenges [31][80] Question: Gross margin improvement and production slowdown - Gross margin improved in Q2 due to mix benefits and lower production slowdowns than expected, but the company expects gross margins to be around 35% in the second half of the year [32][40] Question: IT integration and synergy capture timeline - IT integration is a multiyear project, but some cost reductions and benefits can be realized before full completion [11][29] Question: Competitive environment in infusion systems - The company believes the competitive environment is stable, with customers now able to make decisions as all market participants are available [100] Question: Impact of Tornado in Rocky Mount on IV Solutions - The Tornado in Rocky Mount impacted IV Solutions, with a shortage of Pfizer-supplied products costing the company a few million dollars per quarter [97]